Real-World Prospective Parallel Controlled Study on Endovascular Therapy for Improving Perfusion and Remodeling of TBAD
NCT ID: NCT07022145
Last Updated: 2025-06-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
438 participants
OBSERVATIONAL
2025-06-30
2030-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This project aims to conduct a real-world, prospective, multicenter, parallel-controlled study to compare outcomes between isolated proximal endovascular repair and combined proximal repair with distal bare stent implantation in patients with acute complicated or high-risk type B aortic dissection. The goal is to determine the most effective surgical approach for improving distal perfusion and promoting favorable aortic remodeling, thereby guiding treatment decision-making.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
EndoVascular Aortic Dissection Early vs Delayed
NCT07143071
TEAVR With False Lumen Embolization for Aortic Dissection
NCT07198295
Endovascular Aortic Repair for Aortic Dissection
NCT01505309
A Prospective Study of Discomfort Symptoms in Patients With Aortic Disease After Endovascular Intervention
NCT07114185
The Safety and Effectiveness of Transcatheter Aortic Valve Raplacemet in Intermediate Risk Patients With Bicuspid Aortic Stenosis
NCT03163329
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PSG
Type B aortic dissection patients treated with proximal stent-graft
Endovascular repair
Endovascular repair using proximal stent-graft or proximal stent-graft combined with distal stent for TBAD patients
PSG+DBS
Type B aortic dissection patients treated with proximal stent-graft combined with distal bare stent
Endovascular repair
Endovascular repair using proximal stent-graft or proximal stent-graft combined with distal stent for TBAD patients
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Endovascular repair
Endovascular repair using proximal stent-graft or proximal stent-graft combined with distal stent for TBAD patients
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with acute complicated type B aortic dissection (defined as rupture/imminent rupture, associated ischemic syndromes \[bowel, renal, or lower limb ischemia\], radiologic progression of dissection or aortic dilation during hospitalization, uncontrolled hypertension, or refractory pain lasting over 12 hours), or high-risk type B dissection (defined as total aortic diameter \>40 mm, false lumen diameter \>22 mm, primary entry tear \>10 mm, entry on the inner curvature, hemothorax, radiologic signs of ischemia \[bowel, renal, or lower limb\], or recurrent pain/symptoms).
* Patients deemed suitable for TEVAR or TEVAR combined with supra-aortic single-branch endovascular repair, as assessed by the investigator
* Patients who understand the purpose of the study, voluntarily agree to participate by signing informed consent, and are willing to comply with follow-up requirements
Exclusion Criteria
* Subjects who, due to anatomical factors, are unsuitable for isolated TEVAR or TEVAR combined with supra-aortic single-branch reconstruction
* Subjects with connective tissue disorders, such as Marfan syndrome
* Subjects in poor general condition who cannot tolerate general anesthesia
* Subjects with known allergies to contrast agents or stent materials such as nitinol
* Subjects with a life expectancy of less than 12 months
* Subjects with a history of myocardial infarction or unstable angina within the past 3 months
* Subjects with a history of TIA or cerebral infarction within the past 3 months
* Subjects with serum creatinine levels \>2.5 times the upper limit of normal or currently on dialysis
* Subjects with severe comorbidities such as liver failure
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Zhongshan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhihui Dong
Professor
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023ZD-TEVAR-DBS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.